Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Prostate Cancer

  Free Subscription


13.02.2017

1 Acta Radiol
4 Anticancer Res
1 BJU Int
1 BMC Cancer
1 BMC Urol
5 Br J Radiol
3 Cancer
1 Cancer Res
2 Clin Cancer Res
1 Eur Radiol
7 Eur Urol
1 Int J Urol
1 Invest Radiol
2 J Magn Reson Imaging
4 J Urol
1 JAMA
2 N Engl J Med
1 Nat Rev Urol
1 Oncology
3 PLoS One
1 Prog Urol
7 Prostate
1 Urol Int
1 Urology


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Acta Radiol

  1. SANKINENI S, Smedley J, Bernardo M, Brown AM, et al
    Ferumoxytol as an intraprostatic MR contrast agent for lymph node mapping of the prostate: a feasibility study in non-human primates.
    Acta Radiol. 2016;57:1396-1401.
    PubMed     Text format     Abstract available


    Anticancer Res

  2. MESSINA CS, Weiher H, Schmidt-Wolf IG
    Targeting Prostate Cancer with a Combination of WNT Inhibitors and a Bi-functional Peptide.
    Anticancer Res. 2017;37:555-559.
    PubMed     Text format     Abstract available

  3. LERTSUWAN K, Peters W, Johnson L, Lertsuwan J, et al
    Purinergic Receptor Expression and Cellular Responses to Purinergic Agonists in Human Prostate Cancer Cells.
    Anticancer Res. 2017;37:529-537.
    PubMed     Text format     Abstract available

  4. ABLIN RJ, Owen S, Jiang WG
    Prostate Transglutaminase (TGase-4) Induces Epithelial-to-Mesenchymal Transition in Prostate Cancer Cells.
    Anticancer Res. 2017;37:481-487.
    PubMed     Text format     Abstract available

  5. SHIDA Y, Hakariya T, Takehara K, Onita T, et al
    Comparison Between a Combined Transrectal and Transperineal Approach and a Transrectal Approach for Prostate Rebiopsy.
    Anticancer Res. 2016;36:4685-90.
    PubMed     Text format     Abstract available


    BJU Int

  6. MISRA-HEBERT AD, Hu B, Klein EA, Stephenson A, et al
    Prostate Cancer Screening Practices in a Large, Integrated Health System: 2007-2014.
    BJU Int. 2017 Jan 31. doi: 10.1111/bju.13793.
    PubMed     Text format     Abstract available


    BMC Cancer

  7. LAZARO-IBANEZ E, Lunavat TR, Jang SC, Escobedo-Lucea C, et al
    Distinct prostate cancer-related mRNA cargo in extracellular vesicle subsets from prostate cell lines.
    BMC Cancer. 2017;17:92.
    PubMed     Text format     Abstract available


    BMC Urol

  8. FRAGA A, Ribeiro R, Coelho A, Vizcaino JR, et al
    Genetic polymorphisms in key hypoxia-regulated downstream molecules and phenotypic correlation in prostate cancer.
    BMC Urol. 2017;17:12.
    PubMed     Text format     Abstract available


    Br J Radiol

  9. NITSCHE M, Brannath W, Bruckner M, Wagner D, et al
    Comparison of different contouring definitions of the rectum as organ at risk (OAR) and dose-volume parameters predicting rectal inflammation in radiotherapy of prostate cancer: which definition to use?
    Br J Radiol. 2017;90:20160370.
    PubMed     Text format     Abstract available

  10. O'NEILL AG, Jain S, Hounsell AR, O'Sullivan JM, et al
    Fiducial marker guided prostate radiotherapy: a review.
    Br J Radiol. 2016;89:20160296.
    PubMed     Text format     Abstract available

  11. ALMATANI T, Hugtenburg RP, Lewis RD, Barley SE, et al
    Automated algorithm for CBCT-based dose calculations of prostate radiotherapy with bilateral hip prostheses.
    Br J Radiol. 2016;89:20160443.
    PubMed     Text format     Abstract available

  12. VAN HOLSBEECK A, Degroote A, De Wever L, Vanhoutte E, et al
    Staging of prostatic carcinoma at 1.5 T MRI: correlation of a simplified MRI exam with whole mount radical prostatectomy specimens.
    Br J Radiol. 2016 May 16:20160101.
    PubMed     Text format     Abstract available

  13. JERECZEK-FOSSA BA, Ciardo D, Ferrario S, Fossati P, et al
    No increase in toxicity of pelvic irradiation when intensity modulation is employed: clinical and dosimetric data of 208 patients treated with post-prostatectomy radiotherapy.
    Br J Radiol. 2016;89:20150985.
    PubMed     Text format     Abstract available


    Cancer

  14. KIM H, Kalchman I, Santiago-Jimenez M, Lehrer J, et al
    Transcriptome evaluation of the relation between body mass index and prostate cancer outcomes.
    Cancer. 2017 Jan 31. doi: 10.1002/cncr.30580.
    PubMed     Text format     Abstract available

  15. LAI WS, Gordetsky JB, Thomas JV, Nix JW, et al
    Factors predicting prostate cancer upgrading on magnetic resonance imaging-targeted biopsy in an active surveillance population.
    Cancer. 2017 Jan 31. doi: 10.1002/cncr.30548.
    PubMed     Text format     Abstract available

  16. ARMSTRONG AJ, Saad F, Phung, Dmuchowski C, et al
    Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel.
    Cancer. 2017 Feb 7. doi: 10.1002/cncr.30587.
    PubMed     Text format     Abstract available


    Cancer Res

  17. ALFAQIH MA, Nelson ER, Liu W, Safi R, et al
    CYP27A1 loss dysregulates cholesterol homeostasis in prostate cancer.
    Cancer Res. 2017 Jan 27. pii: canres.2738.2016.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  18. WANG R, Wang J, Gao G, Hu J, et al
    Pre-biopsy mp-MRI can help to improve the predictive performance in prostate cancer: a prospective study in 1478 consecutive patients.
    Clin Cancer Res. 2017 Jan 31. pii: clincanres.2884.2016.
    PubMed     Text format     Abstract available

  19. SAXENA R, Yang C, Rao M, Turaga RC, et al
    Preclinical development of a non-toxic oral formulation of monoethanolamine, a lipid precursor, for prostate cancer treatment.
    Clin Cancer Res. 2017 Feb 6. pii: clincanres.1716.2016.
    PubMed     Text format     Abstract available


    Eur Radiol

  20. SCHIMMOLLER L, Quentin M, Blondin D, Dietzel F, et al
    Targeted MRI-guided prostate biopsy: are two biopsy cores per MRI-lesion required?
    Eur Radiol. 2016;26:3858-3864.
    PubMed     Text format     Abstract available


    Eur Urol

  21. DU C, Chen H, Li C
    Re: Alessandro Morlacco, John C. Cheville, Laureano J. Rangel, Derek J. Gearman, R. Jeffrey Karnes. Adverse Disease Features in Gleason Score 3 + 4 "Favorable Intermediate-risk" Prostate Cancer: Implications for Active Surveillance. Eur Urol. In press
    Eur Urol. 2017 Feb 3. pii: S0302-2838(17)30065.
    PubMed     Text format    

  22. MICHEL MC
    Re: The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients.
    Eur Urol. 2017 Jan 25. pii: S0302-2838(17)30047.
    PubMed     Text format    

  23. EHDAIE B, Assel M, Benfante N, Malhotra D, et al
    A Systematic Approach to Discussing Active Surveillance with Patients with Low-risk Prostate Cancer.
    Eur Urol. 2017 Jan 24. pii: S0302-2838(17)30002.
    PubMed     Text format     Abstract available

  24. MURPHY DG, Risbridger GP, Bristow RG, Sandhu S, et al
    The Evolving Narrative of DNA Repair Gene Defects: Distinguishing Indolent from Lethal Prostate Cancer.
    Eur Urol. 2017 Jan 25. pii: S0302-2838(17)30043.
    PubMed     Text format    

  25. SIVARAMAN A, Barret E
    Reply to Runqiang Yuan and Hongxing Huang's Letter to the Editor re: Ernesto R. Cordeiro Feijoo, Arjun Sivaraman, Eric Barret, et al. Focal High-intensity Focused Ultrasound Targeted Hemiablation for Unilateral Prostate Cancer: A Prospective Evaluatio
    Eur Urol. 2017 Feb 1. pii: S0302-2838(17)30059.
    PubMed     Text format    

  26. ROOBOL MJ, Verbeek JF, van der Kwast T, Kummerlin IP, et al
    Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculator for Initial Prostate Biopsy by Incorporating the 2014 International Society of Urological Pathology Gleason Grading and Cribriform growth.
    Eur Urol. 2017 Feb 2. pii: S0302-2838(17)30058.
    PubMed     Text format     Abstract available

  27. AHMAD AE, Finelli A
    Active Surveillance Discussion for Low-risk Prostate Cancer: Patients' Preferences and Counseling Techniques.
    Eur Urol. 2017 Feb 2. pii: S0302-2838(17)30060.
    PubMed     Text format    


    Int J Urol

  28. ALBERTS AR, Bokhorst LP, Kweldam CF, Schoots IG, et al
    Biopsy undergrading in men with Gleason score 6 and fatal prostate cancer in the European Randomized study of Screening for Prostate Cancer Rotterdam.
    Int J Urol. 2017 Feb 7. doi: 10.1111/iju.13294.
    PubMed     Text format     Abstract available


    Invest Radiol

  29. OTHMAN AE, Falkner F, Weiss J, Kruck S, et al
    Effect of Temporal Resolution on Diagnostic Performance of Dynamic Contrast-Enhanced Magnetic Resonance Imaging of the Prostate.
    Invest Radiol. 2016;51:290-6.
    PubMed     Text format     Abstract available


    J Magn Reson Imaging

  30. LIN YC, Lin G, Hong JH, Lin YP, et al
    Diffusion radiomics analysis of intratumoral heterogeneity in a murine prostate cancer model following radiotherapy: Pixelwise correlation with histology.
    J Magn Reson Imaging. 2017 Feb 8. doi: 10.1002/jmri.25583.
    PubMed     Text format     Abstract available

  31. JAMBOR I, Bostrom PJ, Taimen P, Syvanen K, et al
    Novel biparametric MRI and targeted biopsy improves risk stratification in men with a clinical suspicion of prostate cancer (IMPROD Trial).
    J Magn Reson Imaging. 2017 Feb 6. doi: 10.1002/jmri.25641.
    PubMed     Text format     Abstract available


    J Urol

  32. JEONG IG, Yoo S, Lee C, Kim M, et al
    Obesity as a Risk Factor for Unfavorable Disease in Low-risk Prostate Cancer and Its Relationship with Anatomic Location of Tumor.
    J Urol. 2017 Feb 1. pii: S0022-5347(17)30193-3. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available

  33. BHINDI B, Rangel LJ, Mason RJ, Gettman MT, et al
    Impact of Radical Prostatectomy on Long-Term Oncologic Outcomes in a Matched-Cohort of Men with Pathologic Node-Positive Prostate Cancer Managed with Castration.
    J Urol. 2017 Jan 24. pii: S0022-5347(17)30089-7. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available

  34. PRENDEVILLE S, Nesbitt ME, Evans AJ, Fleshner NE, et al
    Variant Histology and Clinicopathologic Features of Prostate Cancer in Men Aged <50 Years Treated with Radical Prostatectomy.
    J Urol. 2017 Jan 24. pii: S0022-5347(17)30087-3. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available

  35. TRUONG M, Hollenberg G, Weinberg E, Messing EM, et al
    Impact of Gleason Subtype on Prostate Cancer Detection Using Multiparametric MRI: Correlation with Final Histopathology.
    J Urol. 2017 Feb 2. pii: S0022-5347(17)30197-0. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


    JAMA

  36. HIMELSTEIN AL, Foster JC, Khatcheressian JL, Roberts JD, et al
    Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial.
    JAMA. 2017;317:48-58.
    PubMed     Text format     Abstract available


    N Engl J Med

  37. THOMPSON IM JR
    Improved Therapy for PSA Recurrence after Prostatectomy.
    N Engl J Med. 2017;376:484-485.
    PubMed     Text format    

  38. SHIPLEY WU, Seiferheld W, Lukka HR, Major PP, et al
    Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer.
    N Engl J Med. 2017;376:417-428.
    PubMed     Text format     Abstract available


    Nat Rev Urol

  39. KHAN AS, Frigo DE
    A spatiotemporal hypothesis for the regulation, role, and targeting of AMPK in prostate cancer.
    Nat Rev Urol. 2017 Feb 1. doi: 10.1038/nrurol.2016.
    PubMed     Text format     Abstract available


    Oncology

  40. CICERO G, De Luca R, Dorangricchia P, Galvano A, et al
    Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer Patients Progressing after Docetaxel: A Prospective Single-Center Study.
    Oncology. 2017;92:94-100.
    PubMed     Text format     Abstract available


    PLoS One

  41. YU XQ, Luo Q, Smith DP, Clements MS, et al
    Phase of care prevalence for prostate cancer in New South Wales, Australia: A population-based modelling study.
    PLoS One. 2017;12:e0171013.
    PubMed     Text format     Abstract available

  42. KENMOGNE LC, Roy J, Maltais R, Rouleau M, et al
    Investigation of the In Vitro and In Vivo efficiency of RM-532-105, a 17beta-hydroxysteroid dehydrogenase type 3 inhibitor, in LAPC-4 prostate cancer cell and tumor models.
    PLoS One. 2017;12:e0171871.
    PubMed     Text format     Abstract available

  43. LEE CH, Huang G, Chan PH, Hai J, et al
    Androgen deprivation therapy and fracture risk in Chinese patients with prostate carcinoma.
    PLoS One. 2017;12:e0171495.
    PubMed     Text format     Abstract available


    Prog Urol

  44. ALBISINNI S, De Groote A, Deneft F, Thoma P, et al
    [Can preoperative prostate MRI before radical prostatectomy predict extracapsular extension and the side of the index lesion?].
    Prog Urol. 2016;26:281-6.
    PubMed     Text format     Abstract available


    Prostate

  45. ELSHAFAE SM, Kohart NA, Altstadt LA, Dirksen WP, et al
    The Effect of a Histone Deacetylase Inhibitor (AR-42) on Canine Prostate Cancer Growth and Metastasis.
    Prostate. 2017 Feb 9. doi: 10.1002/pros.23318.
    PubMed     Text format     Abstract available

  46. VAN DIE MD, Williams SG, Emery J, Bone KM, et al
    A Placebo-Controlled Double-Blinded Randomized Pilot Study of Combination Phytotherapy in Biochemically Recurrent Prostate Cancer.
    Prostate. 2017 Feb 9. doi: 10.1002/pros.23317.
    PubMed     Text format     Abstract available

  47. LERTSUWAN K, Choe LH, Marwa IR, Lee K, et al
    Identification of Fibulin-1 as a Human Bone Marrow Stromal (HS-5) Sell-Derived Factor That Induces Human Prostate Cancer Cell Death.
    Prostate. 2017 Feb 7. doi: 10.1002/pros.23303.
    PubMed     Text format     Abstract available

  48. NGUYEN HM, Vessella RL, Morrissey C, Brown LG, et al
    LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease an--d Serve as Models for Evaluating Cancer Therapeutics.
    Prostate. 2017 Feb 3. doi: 10.1002/pros.23313.
    PubMed     Text format     Abstract available

  49. ISHARWAL S, Modi S, Arora N, Uhlrich C 3rd, et al
    Minnelide Inhibits Androgen Dependent, Castration Resistant Prostate Cancer Growth by Decreasing Expression of Androgen Receptor Full Length and Splice Variants.
    Prostate. 2017 Feb 1. doi: 10.1002/pros.23298.
    PubMed     Text format     Abstract available

  50. DJUSBERG E, Jernberg E, Thysell E, Golovleva I, et al
    High levels of the AR-V7 Splice Variant and Co-Amplification of the Golgi Protein Coding YIPF6 in AR Amplified Prostate Cancer Bone Metastases.
    Prostate. 2017 Feb 1. doi: 10.1002/pros.23307.
    PubMed     Text format     Abstract available

  51. DJALADAT H, Amini E, Xu W, Cai J, et al
    Oncological Outcomes After Radical Prostatectomy for High-Risk Prostate Cancer Based on New Gleason Grouping System: A Validation Study From University of Southern California With 3,755 Cases.
    Prostate. 2017 Feb 1. doi: 10.1002/pros.23306.
    PubMed     Text format     Abstract available


    Urol Int

  52. LEAO R, Domingos C, Figueiredo A, Hamilton R, et al
    Cancer Stem Cells in Prostate Cancer: Implications for Targeted Therapy.
    Urol Int. 2017 Feb 1. doi: 10.1159/000455160.
    PubMed     Text format     Abstract available


    Urology

  53. KIRK PS, Govani S, Borza T, Hollenbeck BK, et al
    Implications of Prostate Cancer Treatment in Men with Inflammatory Bowel Disease.
    Urology. 2017 Feb 2. pii: S0090-4295(17)30111.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: